Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial.

What Was Tested

The paper reports a study of Albuterol, published as a randomized controlled trial.

Intravenous magnesium can cause bronchodilation in treatment of severe asthma, however its effect by the nebulised route is uncertain.

Who Took Part

The study group was 52 patients.

The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Albuterol study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Albuterol.

A placebo (an inactive look-alike) gave the Albuterol group a baseline to be compared against.

The primary outcome measure was FEV(1) at 90 min.

What Was Measured

Topics PubMed links to this paper include Administration, Inhalation, Albuterol, Asthma, Bronchodilator Agents, Calcium Channel Blockers, Chemotherapy, Adjuvant and Forced Expiratory Volume.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Albuterol in 52 patients.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (Lancet (London, England)), a journal based in England.

More context: all human trials.